Publications
460 publications
- Date
- Relevance
-
GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure
The National Health Care Institute recommends the Minister for Medical Care to extend the reimbursement condition of ...
-
GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation
Zorginstituut Nederland has completed its assessment whether the substance levomepromazine (Nozinan®) can be included in the ...
-
Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)
Zorginstituut Nederland has completed its assessment whether the further conditions of SGLT-2 inhibitors canagliflozin ...
-
GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine
The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...
-
GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage
The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...
-
GVS advice drospirenon-estetrol (Drovelis®)
The National Health Care Institute has completed its assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with ...
-
Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)
Zorginstituut Nederland recommends that larotrectinib (Vitrakvi®) should be conditionally included in the basic health care ...
-
Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)
Zorginstituut Nederland recommends that entrectinib (Rozlytrek®) should be conditionally included in the basic health care ...
-
Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
The National Health Care Institute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...
-
GVS advice on the reassessment of tafamidis (Vyndaqel®)
The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...